Compare Hims and Hers Health Inc (HIMS) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Symbotic Inc — how do they compare? Hims and Hers Health Inc trades at $29.4 (market cap $6.55B), while Symbotic Inc trades at $42.37 (market cap $5.46B). The key difference: Hims and Hers Health Inc is the larger of the two by market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Symbotic Inc for 23 Days on average.
| HIMS | SYM | |
|---|---|---|
Market Cap | $6.55B | $5.46B |
Volume | 14,842,814 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $62.76 | $87.30 |
52-Week Low | $14.52 | $38.22 |
Typical Hold Time | 21 Days | 23 Days |
Enterprise Value | $7.25B | $3.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
SYM trades at $42.73, down 1.34% today, with bearish technical signals dominating. The stock shows mixed fundamentals with strong revenue growth projected ($2.6B in 2026) but negative 2025 net income of -$16.94M. Recent earnings show two misses against expectations, though Q4 2025 beat estimates. Analyst consensus remains positive with 61% buy ratings and a $60.33 price target, representing 41% upside potential from current levels.
The outlook balances growth potential against execution risks. SYM's $22.5B backlog and expanding AI/robotics market position offer substantial upside, but customer concentration (85% Walmart revenue) and recent earnings misses create near-term uncertainty. Technical indicators suggest caution with bearish moving average signals, though oversold conditions may present entry opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
